The CHARM network will be established through three primary institutions-Beth IsraelDeaconess Medical Center (BIDMC), the University of California San Diego (UCSD), and theUniversity of Washington (UW)-along with their subcontracting institutions. At UCSD andpartner sites, the CHARM network will be implemented via the PREVENT project. All PREVENTparticipants will be consented in to Component A0 (Community Testing) and a subset of A0participants will be invited to participate and will be consented into the othercomponents: Component A (Ongoing Testing); Component A Sub-study (Immunology); ComponentB (Household Transmission).Component A0 participants (Community testing) will be members of the community who areinterested in accessing testing for respiratory infections and will be asked to providelimited information that will then be used for screening for study Components A and/or B.Participants in Component A (Ongoing Testing ) will undergo weekly symptom screening. Ifthey report symptoms, they will be asked to provide a nasal swab and complete illnessquestionnaires on the day they report symptoms (Day 0) and again on Days 7 and 14.Participants in Component A Sub-study (Immunology) will provide blood and saliva/nasalfluid samples twice a year, as well as before and after infection and/or immunizationagainst priority pathogens.Participants in Component B (Household Transmission) will complete daily symptomquestionnaires and nasal swabs for 14 days following enrollment, regardless of symptoms.Those who are symptomatic at enrollment will also complete retrospective daily diariesfrom symptom onset to the enrollment date. Additionally, they provide blood and/orsaliva/nasal fluid samples at enrollment and again 28 days later.For all Components, UCSD will provide PCR test results for SARS-CoV-2, Influenza A/B, andRSV for nasal swab samples.
Not Provided
Other: Component A0
It will be implemented as a recruitment strategy. This strategy will enable members of
the community to access no cost testing for respiratory infections. If a participant
feels sick or thinks they have been exposed to a respiratory infection and wants to be
tested, they can complete a symptoms and exposure survey in the PREVENT APP, retrieve a
PCR test kit from a vending machine using a unique code received through the PREVENT APP,
self-collect an anterior nares nasal swab following instructions provided, and return the
test kit at one of the vending machines or drop off locations for the EXCITE lab to pick
up and process. The anterior nares nasal swab will be tested for SARS-CoV-2, influenza,
Respiratory Syncytial Virus, and other germs (viruses or bacteria) that cause respiratory
infections. At the time of consent and registration for the Community Testing Component,
participants will be used to screen for Cohorts A/B.
Other: Component A1
Participants will be invited to 'test' out the PREVENT App and a provide a 'baseline'
sample to ensure competency for requesting a nasal swab, retrieving the test kit from a
vending machine, self-collecting a sample, and returning the test for PCR testing, with
the assistance of study staff. Weekly Symptom Surveys, Annual Surveys, and immunization
status.
Other: Component A2
Investigators will collect immunologic specimens from a subset of participants in
Component A (the subset herein referred to as Component A immunologic sub-study).
Investigators will combine testing data from these immunologic specimens with multiple
data elements already captured in Component A (such as data from pathogen testing and
sequencing, survey data, medical records, or immunization services) and Component B
(serum obtained at enrollment and 28 post-enrollment) to meet sub-study objectives.
Overall, the Component A sub-study will provide critical insight into the immune response
to respiratory pathogen infections and immunizations.
Other: Component B
Participants will be asked to complete the enrollment survey after enrolling in Component
B if the survey has not already been completed as part of Component A. They will also be
asked to complete:
1. Daily anterior nares nasal swab collection
2. All household participants, including the index case, will be asked to self-collect
an enrollment swab and daily nasal swab specimens for 14 days and return them for
testing.
3. Mucosal specimen collection
4. Survey data collection
Community Testing Component:
Inclusion:
- All community members are able to participate in the community testing component.
Exclusion:
- There is no exclusion criteria and participants will not be excluded based on pregnancy
status or age.
For Component A:
Inclusion:
- All ages
- AND Lives in service area of a recruitment center (i.e., within range of courier
pick up)
- AND Plans to remain living in a recruitment area for the next 2 years.
Exclusion:
- Inability to communicate in a language in which consent forms, materials, etc. are
available
- OR Incarcerated
- OR Living in a congregate setting (e.g., assisted living, nursing home, university
dormitories with shared bathroom and communal eating facilities)
- OR Unable/unwilling to participate in planned data and specimen collections
- OR Unable to comply with study procedures, as determined by study investigators
- OR Participation in clinical trials of investigational agents for respiratory viral
infections during the three months prior to enrollment and for the duration of the
study.
For Component B:
Inclusion:
Index case:
- Detection of priority respiratory pathogen via laboratory or point-of-care test on
the day of eligibility screening or in the previous 5 days, AND
- Lives in service area of a recruitment center (i.e., within range of courier pick
up), AND
- Lives in a household with ≥1 other person and plans to remain in the household for
at least the duration of specimen collection (i.e., 14 days), AND
- Has not been hospitalized since the date of symptom onset.
Household contacts:
- Routinely sleep in the same household as index case and slept in household ≥1 night
in the 7 days before index case symptom onset, AND
- Plan to remain in the household for at least the duration of specimen collection
(i.e., 14 days).
Household:
- There is ≥1 non-ill household member (i.e., asymptomatic and has not tested positive
for the virus of the index case) on the day of eligibility screening or in the
previous 5 days,
- AND all symptomatic persons in the household had a symptom or diagnosis onset date
on the day of eligibility screening or in the previous 5 days.
Exclusion:
Index case:
- Lives in a congregate setting (e.g., assisted living, nursing home, university
dormitories with shared bathroom and communal eating facilities)
- Meet any A1 exclusion criteria
Household contacts:
- Has been hospitalized any time since date of primary case symptom onset
- Meets any A1 exclusion criteria
Household:
- The enrollment visit occurs >6 days after the first symptom onset of primary case
- The primary case in the household is not enrolled
- The primary case has been hospitalized any time after the date of symptom onset
UC San Diego
La Jolla, California, United States
San Ysidro Health
San Ysidro, California, United States
Breanna Reyes, MPH
8589454553
prevent@health.ucsd.edu
PREVENT Project
8589454553
prevent@health.ucsd.edu
Not Provided